.svg)
International Consensus Document: Callular, Acellular, and Matrix-Like Products in Pressure Injuries
Based on these results, future studies should be conducted that further investigate the use of this novel human keratin matrix graft for the treatment of chronic DFUs.
Editorial lead: Benjamin Snakefield Associate publisher: Tracy Cowan Head of projects: Camila Fronzo Managing director: Rob Yates rob.yates@markallengroup.com CEO: Ben Allen Published by MA Healthcare Ltd St Jude’s Church, Dulwich Road, London, SE24 0PB, UK +44 (0)20 7738 6726 www.markallengroup.com Produced by Mark Allen Medical Communications www.mamedcomms.com © MA Healthcare Ltd 2025 Medical writer All rights reserved. No reproduction, transmission or copying of this publication is allowed without written permission. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanical, electronic, photocopying, recording, or otherwise, without the prior written permission of MA Healthcare or in accordance with the relevant copyright legislation. Jessica Hoge, Medical Director and CEO, Apricity Medical PLLC, US Sponsored by BioStem Technologies and Venture Medical
Executive summary
● The high prevalence and recurrence of pressure injuries (PIs) require new treatment strategies.
● The goals of PI treatment and research should be holistic, encompassing quality of life, symptom control, patient-directed goals of care and survival, as well as cure.
● Cellular, acellular and matrix-like products (CAMPs) are advanced wound-care tools that promote innate healing processes, such as stimulating fibroblast activity, granulation tissue formation and keratinocyte migration.
● CAMPs have been shown to be safe and effective in full-thickness PIs and other hard-to-heal wounds.
● Indications for CAMPs should include early application in complex wounds, multiple comorbidities or impaired healing capacity, with or without exposed deep structures.
● Patient selection should consider absolute and relative contraindications for CAMPs, as well as differential diagnoses for PIs, such as skin failure and malignant or atypical wounds.
● Patients treated with CAMPs require optimisation of offloading, mobility and tissue perfusion, along with addressing nicotine use and polypharmacy, as well as skin protection, nutrition and psychosocial support.
● Application of CAMPs must be preceded by wound-bed preparation encompassing tissue debridement, inflammation/infection control, moisture management and optimisation of patient and social factors.
● CAMPs should be applied in a clean environment following instructions for use, potentially supported by negative pressure wound therapy.
● Use of CAMPs requires ongoing documentation and re-assessment of treatment efficacy and quality of life, with onward referral for osteomyelitis, fistulas or other arterial disease.
● CAMPs use should be based in multidisciplinary collaboration and supported by patient and professional education. © 2025 MA Healthcare Ltd © 2025 MA Healthcare Ltd
● The appropriate use of CAMPs in PIs should be applied across all payors and relevant sites of service.
● Research on CAMPs in PIs should make wider use of real-world data to support the limited number and narrow scope of randomised control trials.
Read The Entire Article:
Popular Research
Categories
A multicentre clinical trial evaluating the outcomes of two application regimens of a unique keratin-based graft in the treatment of Wagner grade one non-healing diabetic foot ulcers
Based on these results, future studies should be conducted that further investigate the use of this novel human keratin matrix graft for the treatment of chronic DFUs.
Real-world evaluation of cellular, acellular, and matrix-like products for pressure ulcers in the post-acute setting
This observational comparative effectiveness study analyzed de-identified data from the LiftOff Registry, a national database encompassing more than 18,000 patients and 23,000 pressure ulcers (PUs) treated in long-term acute care hospitals and skilled nursing facilities.
Retention processed placental membrane versus standard of care in treating diabetic foot ulcers
Diabetic foot ulcers (DFUs) are a severe complication for diabetic patients, significantly impacting patient quality of life and healthcare system efficiency. Traditional standard of care (SOC) treatments are inadequate for many patients, necessitating the use of advanced wound care products, such as human placental membranes.
A multicentre clinical trial evaluating the outcomes of two application regimens of a unique keratin-based graft in the treatment of Wagner grade one non-healing diabetic foot ulcers
Diabetic foot complications that lead to lower extremity amputations pose a significant challenge to the entire global health system.
Assessing placental membrane treatment efficiency in diabetic foot ulcers: Processing for retention versus lamination
Diabetic foot ulcers are a severe complication in diabetic patients, significantly impact healthcare systems and patient quality of life, often leading to hospitalization and amputation.
